第四屆台日醫藥交流會議議程 4th Joint Conference of Taiwan and Japan on Medical Products Regulation

Date: 7th December 2016

Venue: Nihonbashi Life Science HUB (Joint session and pharmaceuticals/ Health Insurance session), Nihonbashi Life Science Bldg.10F (Medical devices session)

	Joint Session		
08:30-09:00	Registration		
09:00-09:30	Opening Remarks		
	Mr. Hitoshi Funamachi, Senior Executive Director, Interchange Association,		
	Japan		
	Mr. Hou-Chun CHANG, Director, Economic Division, Taipei Economic and		
	Cultural Representative Office in Japan		
	Mr. Kazuhiko Mori, Councilor, MHLW		
	Dr. Shiow-Ing Wu, Deputy Director-General, TFDA		
	Mr. Tadaharu Goto, Director General, JPMA		
	Mr. Tung-Mao Su, Standing Director, Taiwan Pharmaceutical		
	Manufacturer's Association		
	Mr. Koji Nakao, President, JFMDA		
	Mr. Chi-Chung Huang, Chairman, Taiwan Medical and Biotech Industry		
	Association		
09:30-09:40	Memorial Photo Taking		
	Regulatory Updates for Medical Products in Japan and Taiwan		
	(Moderator: Mr. Yoshihiko Sano (MHLW))		
	(1). Amendments in regulations and future prospects		
	(2). Sharing of experience on new medical products		
09:40-10:40	1. Dr. Toshiyoshi Tominaga, Associate Executive Director for		
	International Programs, PMDA (25min)		
	2. Ms. Chao-Yi Wang, Director, Division of Medicinal Products, TFDA		
	(25min)		
	3. Q and A (10min)		
10:40-10:55	Coffee Break		

	Parallel Session (Pharmaceuticals)				
	Мо	oderator: Ms. Chao-Yi Wang (TFDA)			
	w	Gs Progress Report			
		-New drugs			
		Dr. Yi-Chu Lin, Section Chief, Division of Medicinal Products, TFDA			
		(8min)			
		-GCP			
		Mr. Ryosuke Sakai, Inspector, Office of Non-clinical and Clinical			
		Compliance, PMDA (8min)			
10.55 11.55		-OTC drugs			
10:55-11:55		Mr. Hung-Jung Lien, Section Chief, Division of Medicinal Products,			
		TFDA (8min)			
		-OTC drugs			
		Mr. Fumihito Takanashi, Assistant Director, Office of International			
		Regulatory Affairs, MHLW (8min)			
		-Generic drugs			
		Mr. Naoyuki Yasuda, Office Director, Office of International Programs,			
		PMDA (8min)			
		Panel Discussion (20min)			
11:55-13:00		Luncheon			
	Mo	oderator: Mr. Naoyuki Yasuda (PMDA)			
	1.	New Strategies and Technologies			
	(1)	3D printing			
		Prof. Jeng-Ywan Jeng, National Taiwan University of Science and			
13:00-13:50		Technology (20min)			
	(2)	Electronic tools used in safety measures			
		Mr. Atsushi Noguchi, Coordinator, Office of Medical Informatics and			
1					
		Epidemiology, PMDA (20min)			
		Epidemiology, PMDA (20min) Panel Discussion (10min)			
	Ма				
	Мс 2.	Panel Discussion (10min)			
	_	Panel Discussion (10min) oderator: Dr. Churn-Shiouh Gau (CDE)			
13: 50-15:05	2.	Panel Discussion (10min) oderator: Dr. Churn-Shiouh Gau (CDE) Experience Sharing on maintaining safety and quality of			
13: 50-15:05	2.	Panel Discussion (10min) oderator: Dr. Churn-Shiouh Gau (CDE) Experience Sharing on maintaining safety and quality of pharmaceuticals			
13: 50-15:05	2.	Panel Discussion (10min) oderator: Dr. Churn-Shiouh Gau (CDE) Experience Sharing on maintaining safety and quality of pharmaceuticals Regulatory perspective			

TFDA (15min)Consideration point of post-approval change Mr. Go Yamamoto, Deputy Director, Pharmaceutical Evaluation Division, MHLW (15min)Description of the demanded document of API for the application of registration of generic medicine in Japan Mr. Ryosuke Kuribayashi, Chief Reviewer, Office of Generic Drugs, PMDA (15min)(2) Industry perspectivePost-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min)Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min)15:05-15:20Coffee BreakModerator: Mr. Yoshihiko Sano (MHLW)3. Post-marketing Management (1) Safety information (including vaccine) report and research in Japan
 Mr. Go Yamamoto, Deputy Director, Pharmaceutical Evaluation Division, MHLW (15min) Description of the demanded document of API for the application of registration of generic medicine in Japan Mr. Ryosuke Kuribayashi, Chief Reviewer, Office of Generic Drugs, PMDA (15min) Industry perspective Post-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min) Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
 Division, MHLW (15min) Description of the demanded document of API for the application of registration of generic medicine in Japan Mr. Ryosuke Kuribayashi, Chief Reviewer, Office of Generic Drugs, PMDA (15min) (2) Industry perspective Post-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min) Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
 Pescription of the demanded document of API for the application of registration of generic medicine in Japan Mr. Ryosuke Kuribayashi, Chief Reviewer, Office of Generic Drugs, PMDA (15min) Industry perspective Post-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min) Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Moderator: Mr. Yoshihiko Sano (MHLW) Post-marketing Management
 registration of generic medicine in Japan Mr. Ryosuke Kuribayashi, Chief Reviewer, Office of Generic Drugs, PMDA (15min) (2) Industry perspective Post-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min) Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
 Mr. Ryosuke Kuribayashi, Chief Reviewer, Office of Generic Drugs, PMDA (15min) (2) Industry perspective Post-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min) Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
 PMDA (15min) (2) Industry perspective Post-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min) Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Coffee Break Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
(2) Industry perspective- Post-approval change applicationDr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min)- Post-approval change applicationMr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee,Quality & Technology Committee, JPMA (10min)Panel Discussion (10min)15:05-15:20Coffee BreakModerator: Mr. Yoshihiko Sano (MHLW)3. Post-marketing Management
 Post-approval change application Post-approval change application Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min) Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Coffee Break Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
Dr. Alice Hsu, Standard Chemical & Pharmaceutical Co, TW (10min)Post-approval change applicationMr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee,Quality & Technology Committee, JPMA (10min)Panel Discussion (10min)15:05-15:20Moderator: Mr. Yoshihiko Sano (MHLW)3. Post-marketing Management
 Post-approval change application Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Coffee Break Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
Mr. Tomonori Nakagawa, Asia Project Leader, GMP Sub Committee, Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Coffee Break Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
Quality & Technology Committee, JPMA (10min) Panel Discussion (10min) 15:05-15:20 Coffee Break Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
Panel Discussion (10min) 15:05-15:20 Coffee Break Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
15:05-15:20 Coffee Break Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
Moderator: Mr. Yoshihiko Sano (MHLW) 3. Post-marketing Management
3. Post-marketing Management
(1) Safety information (including vaccine) report and research in Japan
Dr. Daisaku Sato, Division Director, Safety Division, MHLW(15min)
15:20-16:20
- Current Status and policy direction on "Adverse Event Reporting"
Ms. Wen-Wen Chen, CEO, Taiwan Drug Relief Foundation (15min)
 Current Status and policy direction on "Adverse Event Reporting"
Ms. Mariko Tsukuda, Reviewer, Office of Safety I, PMDA (15min)
Panel Discussion (15min)
Parallel Session (Health Insurance)
Moderator: Mr. Yoshihiko Sano (MHLW)
Update on regulations in NHI pricing and related policy
-Current update in NHI policy and future directions
Mr. Hiroaki Mamiya, Section Chief, Economic Affairs Division,
16:20-17:20 MHLW (20min)
-Current update in NHI policy and future directions
Mr. Chang-Jr Chen, Specialist, Medical Review and Pharmaceutical
Benefits Division, NHIA (20min)
Panel discussion (20min)

Pharmaceuticals & Health Insurance			
	Closing Remarks		
17:20-17:30	- Ms. Chao-Yi Wang, Director, Division of Medicinal Products, TFDA		
	- Dr. Toshiyoshi Tominaga, Associate Executive Director, PMDA		
18:00-	Welcome Reception (Nihonbashi Life Science Bldg.10F)		

Parallel Session (Medical Devices)				
Moderator: Ms. Yumiko Aoyagi (MHLW)				
	1. Progress of Product Registration WG			
11:15-11:45	- Dr. Ta-Jen Wu, Technical Specialist, Division of Medical Devices and			
	Cosmetics, TFDA (15min)			
	Panel Discussion (15min)			
11:45-13:15	Luncheon			
	Moderator: Ms. Yumiko Aoyagi (MHLW)			
	2. Progress of QSD/QMS WG			
13:15-13:45	- Mr. Katsuya Sawadaishi, Inspector, Division of Medical Devices, Office			
	of Manufacturing/ Quality and Compliance, PMDA (15min)			
	Panel Discussion (15min)			
	Moderator: Mr. Ming-Shin Lee, Director, Division of Risk Management,			
	(Taiwan FDA)			
	3. Information sharing on recent topics			
	- Software validation			
	Mr. Tzu-Wei Li, Industrial Technology Research Institute of Taiwan			
	(20min)			
13:45-15: 30	Mr. Keiichiro Ozawa, FUJIFILM Corporation (20min)			
	- In Vitro Companion Diagnostic Devices			
	Mr. Tzu-Wei Li, Industrial Technology Research Institute of Taiwan			
	(20min)			
	Ms. Yumiko Aoyagi, Deputy Director, Medical Device Evaluation			
	Division, MHLW (20min)			
	Panel Discussion (25min)			
	Closing Remarks			
	- Ms. Yu-Roo Chu, Deputy Director, Division of Medical Devices and			
15:30-15:40	Cosmetics, TFDA			
	-Dr. Yuka Suzuki, International Coordination Officer, Office of			
	International Programs, PMDA			

15:40-16:00	Coffee Break
	Closed Meeting
16:00-17:30	1. Product Registration WG closed meeting
	2. QSD/ QMS WG closed meeting
18:00~	Welcome Reception (Nihonbashi Life Science Bldg.10F)